This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
46
Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
Novo Nordisk Investigational Site
Neuss, Germany
Area under the glucose infusion rate curve
Time frame: From 0 to 12 hours
Area under the serum insulin aspart concentration-time curve
Time frame: From 0 to 12 hours
Maximum glucose infusion rate
Time frame: Within 0 to 12 hours after dosing
Maximum observed serum insulin aspart concentration
Time frame: Within 0 to 12 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.